Keppra
Electroencephalographic Neonatal Seizures
UCB Biopharma SRLPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Electroencephalographic Neonatal Seizures cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE UCB Biopharma SRL | Phase 3 | B |
MIDAZOLAM UCB Biopharma SRL | Phase 3 | B |
Brivaracetam UCB Biopharma SRL | Phase 3 | B |
PHENYTOIN UCB Biopharma SRL | Phase 3 | B |
Lacosamide UCB Biopharma SRL | Phase 2 | CCC |
Phenobarbital UCB Biopharma SRL | Phase 3 | CCC |
Same molecule, other indications
Keppra is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →